Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026

      PAQ

      News provided by

      PAQ Therapeutics

      Nov 20, 2026, 07:00 ET

      Share this article

      Share this article


      – No dose-limiting toxicities observed across doses from 10 to 750 mg, with no PT0253-specific pre-treatment prophylaxis required –

      – Monotherapy antitumor activity observed in colorectal and pancreatic cancers, including a partial response in a patient previously treated with a KRAS-targeted agent and disease control in 50% of patients who had progressed on prior (K)RAS-targeted therapy –

      – Promising combination activity observed in first-line metastatic pancreatic cancer, with objective responses in 6 of 7 patients with at least two scans –

      BURLINGTON, Mass., Nov. 20, 2026 /PRNewswire/ -- PAQ Therapeutics, a clinical-stage biotechnology company focused on advancing targeted protein degradation to address the unmet medical needs of patients with KRAS-driven cancers, today announced first clinical data from its ongoing Phase 1 trial of PT0253 (NCT06797336). Alexander I. Spira, M.D., Ph.D., FACP, FASCO, of NEXT Oncology Virginia, presented the data in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain.

      The initial clinical findings demonstrate a differentiated safety profile for PT0253, encouraging monotherapy antitumor activity, including in patients previously treated with (K)RAS-targeted therapies, and promising early combination activity with standard-of-care chemotherapy in first-line metastatic pancreatic cancer. These findings support the potential of KRAS degradation to address resistance mechanisms that may limit KRAS inhibitors, while offering a differentiated approach to sustained KRAS target suppression and improved safety profile.

      Monotherapy Dose Escalation

      As of October 23, 2026, 44 patients with KRAS G12D-mutant advanced solid tumors had received weekly intravenous PT0253 at doses ranging from 10 to 750 mg. Patients had received a median of 2.5 prior therapies, and 27% had received prior (K)RAS-targeted therapy.

      Safety: No dose-limiting toxicities (DLTs) were observed across the full dose range of 10 to 750 mg. At doses of 120 to 750 mg (n=27), treatment-related adverse events (TRAEs) were predominantly Grade 1–2. One patient (4%) experienced a Grade ≥3 TRAE. There were no serious TRAEs or discontinuations due to TRAEs. No PT0253-specific pre-treatment prophylaxis was required.

      Antitumor activity: PT0253 monotherapy demonstrated antitumor activity across dose levels, with partial responses (PRs) observed at doses of 120 mg and above in patients with colorectal, pancreatic and lung cancers.

      • Colorectal cancer: At doses of 120 mg and above, 3 of 6 patients with refractory colorectal cancer achieved partial responses (PRs, unconfirmed), including one patient whose disease had progressed on a prior (K)RAS-targeted agent. These findings are encouraging in the context of the hypothesis that catalytic degradation of KRAS G12D may address EGFR-mediated feedback reactivation associated with KRAS inhibition.
      • Pancreatic cancer: At doses of 120 mg and above, 3 of 10 (K)RAS therapy-naïve patients had confirmed PRs, with most responses deepening over time. Nine of 10 patients achieved disease control.
      • Following prior (K)RAS-targeted therapy: Among 12 patients whose disease had progressed on prior (K)RAS-targeted therapy, 6 (50%) achieved disease control, demonstrating encouraging early activity in this difficult-to-treat population.

      First-Line Metastatic Pancreatic Cancer: PT0253 + mFOLFIRINOX

      Fourteen patients received PT0253 350 mg once weekly in combination with modified FOLFIRINOX (mFOLFIRINOX), a standard-of-care chemotherapy regimen, and 13 remained on treatment as of the October 23, 2026 data cutoff.

      Among the 7 patients with at least two scans, 6 achieved objective responses: one confirmed complete response (CR) and five PRs, four of which were confirmed.

      The combination was generally well tolerated, with a safety profile consistent with mFOLFIRINOX alone and low gastrointestinal toxicity without PT0253-specific prophylaxis. Median relative dose intensity was 91% for PT0253, while mFOLFIRINOX dose intensity was 75–80% across components, consistent with the expected range for this chemotherapy regimen.

      These early findings support further investigation of PT0253 in combination with standard-of-care chemotherapy in first-line pancreatic cancer.

      "We are encouraged by these initial clinical data for PT0253. Its differentiated safety profile, monotherapy antitumor activity and promising early combination results support our strategy of advancing KRAS protein degradation as a new therapeutic approach," said Nan Ji, Ph.D., Chief Executive Officer of PAQ Therapeutics. "We look forward to further evaluating PT0253 in pancreatic and colorectal cancer expansion cohorts."

      "PT0253 as a monotherapy was well tolerated across the full dose range without pre-treatment prophylaxis. Importantly, in combination with mFOLFIRINOX in first-line pancreatic cancer, patients received chemotherapy at its expected relative dose intensity," said Andrew P. Krivoshik, M.D., Chief Medical Officer of PAQ Therapeutics. "With no dose-limiting toxicities and a high rate of deep responses, the first-line combination data are an important demonstration of combinability with standard-of-care therapy."

      "Patients with KRAS G12D-mutant cancers who progress on chemotherapy, and increasingly on KRAS-targeted therapies, have few options," said Dr. Spira. "It is encouraging to see antitumor activity, including a partial response and disease control, in patients whose disease had progressed on prior (K)RAS-targeted therapy. The favorable tolerability observed across the dose range and in combination with standard-of-care chemotherapy is also encouraging. The expansion cohorts will be important to further evaluate these early findings."

      About PT0253

      PT0253 is an investigational, intravenously administered small-molecule degrader that selectively eliminates the KRAS G12D mutant protein. It is designed to address resistance mechanisms observed with (K)RAS inhibitors, provide sustained KRAS target suppression, and improve safety profile.

      The Phase 1 clinical trial of PT0253 is designed to evaluate safety and tolerability, and to determine the maximally tolerated dose and/or recommended Phase 2 dose of PT0253 in adult patients with KRAS G12D-mutant advanced solid tumors.

      About PAQ Therapeutics

      PAQ Therapeutics is a clinical-stage biotechnology company focused on advancing targeted protein degradation to address the unmet medical needs of patients with KRAS-driven cancers. PAQ's clinical pipeline comprises PT0253, a selective KRAS G12D degrader, and PT0511, a pan-KRAS degrader, both in Phase 1 development for patients with advanced solid tumors. The company is based in Burlington, Massachusetts.

      Forward-Looking Statements

      This press release contains forward-looking statements regarding the development and potential of PT0253 and the timing of future data. Preliminary data may change as more patient data become available, and early results may not predict later trial results. PAQ undertakes no obligation to update these statements except as required by law.

      Data qualification: Clinical data are preliminary and subject to ongoing data monitoring.

      SOURCE PAQ Therapeutics

      Modal title

      Also from this source

      PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium

      PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium

      PAQ Therapeutics, a clinical-stage biotechnology company developing targeted protein degraders for KRAS-driven cancers with significant unmet medical ...

      PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader

      PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader

      PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      Pharmaceuticals

      Pharmaceuticals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.